Association of aldose reductase gene Z+2 polymorphism with reduced susceptibility to diabetic nephropathy in Caucasian Type 1 diabetic patients

被引:21
作者
Lajer, M
Tarnow, L
Fleckner, J
Hansen, BV
Edwards, DG
Parving, HH
Boel, E
机构
[1] Novo Nordisk AS, Dept Mol Genet, DK-2880 Bagsvaerd, Denmark
[2] Steno Diabet Ctr, DK-2820 Gentofte, Denmark
[3] Novo Nordisk AS, Dept Biostat, DK-2880 Bagsvaerd, Denmark
[4] Univ Aarhus, Fac Hlth Sci, Aarhus, Denmark
关键词
aldose reductase; diabetic nephropathy; microvascular complications; Type; 1; diabetes;
D O I
10.1111/j.1464-5491.2004.01259.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims The Z-2 allele of the (AC)(n) polymorphism in the aldose reductase gene (ALR2) confers increased risk of microvascular diabetic complications, whereas the Z+2 allele has been proposed to be a marker of protection. However data are conflicting. Therefore, we investigated whether this polymorphism is associated with diabetic nephropathy and retinopathy in Type 1 diabetes mellitus in a large case-control study and a family-based analysis. Methods A total of 431 Type 1 diabetic patients with diabetic nephropathy and 468 patients with longstanding Type 1 diabetes and persistent normoalbuminuria were genotyped for the case-control study. In addition, 102 case trios and 98 control trios were genotyped for a family-based study. Results Thirteen different alleles were identified. In the case-control study, the Z+2 allele frequency was significantly higher in the normoalbuminuric diabetic than in patients with diabetic nephropathy (0.17 vs. 0.11, P = 0.008), suggesting a protective function of the Z+2 allele. No significant increase in the frequency of the putative risk allele Z-2 was found in patients with diabetic nephropathy vs. controls (0.39 vs. 0.36). No association with diabetic retinopathy was found. Although the results of the transmission of the Z-2 and Z+2 alleles in the independent family-based study were consistent with the association study, the number of informative families was limited and thus differences were not statistically significant. Conclusions The Z+2 allele of the ALR2 promoter polymorphism is associated with a reduced susceptibility to diabetic nephropathy in Danish Type 1 diabetic patients, suggesting a minor role for the polyol pathway in the pathogenesis of diabetic kidney disease. No association of the ALR2 polymorphism with diabetic retinopathy was found.
引用
收藏
页码:867 / 873
页数:7
相关论文
共 33 条
[1]   SORBINIL PREVENTS GLOMERULAR HYPERPERFUSION IN DIABETIC RATS [J].
BANK, N ;
MOWER, P ;
AYNEDJIAN, HS ;
WILKES, BM ;
SILVERMAN, S .
AMERICAN JOURNAL OF PHYSIOLOGY, 1989, 256 (06) :F1000-F1006
[2]  
Close CF, 1999, DIABETIC MED, V16, P918
[3]  
Demaine A, 2000, INVEST OPHTH VIS SCI, V41, P4064
[4]  
Dyer PH, 1999, DIABETOLOGIA, V42, P1030
[5]   FAMILIAL CLUSTERING OF CARDIOVASCULAR-DISEASE IN PATIENTS WITH INSULIN-DEPENDENT DIABETES AND NEPHROPATHY [J].
EARLE, K ;
WALKER, J ;
HILL, C ;
VIBERTI, G .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (10) :673-677
[6]  
GREENE DA, 1987, NEW ENGL J MED, V316, P599
[7]   CRUCIAL ROLE OF ALDOSE REDUCTASE-ACTIVITY AND PLASMA-GLUCOSE LEVEL IN SORBITOL ACCUMULATION IN ERYTHROCYTES FROM DIABETIC-PATIENTS [J].
HAMADA, Y ;
KITOH, R ;
RASKIN, P .
DIABETES, 1991, 40 (10) :1233-1240
[8]   Polymorphism in the 5'-end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type I diabetes [J].
Heesom, AE ;
Hibberd, ML ;
Millward, A ;
Demaine, AG .
DIABETES, 1997, 46 (02) :287-291
[9]   Aldose reductase expression is induced by hyperglycemia in diabetic nephropathy [J].
Hodgkinson, AD ;
Sondergaard, KL ;
Yang, BM ;
Cross, DF ;
Millward, BA ;
Demaine, AG .
KIDNEY INTERNATIONAL, 2001, 60 (01) :211-218
[10]   Association of an (A-C)n dinucleotide repeat polymorphic marker at the 5′-region of the aldose reductase gene with retinopathy but not with nephropathy or neuropathy in Japanese patients with Type 2 diabetes mellitus [J].
Ichikawa, F ;
Yamada, K ;
Ishiyama-Shigemoto, S ;
Yuan, X ;
Nonaka, K .
DIABETIC MEDICINE, 1999, 16 (09) :744-748